Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in Japanese cancer patients and the efficacy of immunotherapy remain unknown. Methods We investigated the gut microbiota of 26 patients with solid tumors prior to immune checkpoint inhibitor monotherapy to identify bacteria involved in the efficacy of these drugs and immune-related adverse events (irAEs). Results The genera Prevotella and Parabacteroides were relatively common in the group showing efficacy towards the anti-PD-1 antibody treatment (effective group). The proportions of Catenibacterium (P = 0.022) and Turicibacter (P = 0.049) were significantly higher in the effective group than in the ineffective group. In addition, the proportion of Desulfovibrion (P = 0.033) was significantly higher in the ineffective group. Next, they were divided into irAE and non-irAE groups. The proportions of Turicibacter (P = 0.001) and Acidaminococcus (P = 0.001) were significantly higher in the group with irAEs than in those without, while the proportions of Blautia (P = 0.013) and the unclassified Clostridiales (P = 0.027) were significantly higher in the group without irAEs than those with. Furthermore, within the Effective group, Acidaminococcus and Turicibacter (both P = 0.001) were more abundant in the subgroup with irAEs than in those without them. In contrast, Blautia (P = 0.021) and Bilophila (P= 0.033) were statistically significantly more common in those without irAEs. Discussion Our Study suggests that the analysis of the gut microbiota may provide future predictive markers for the efficacy of cancer immunotherapy or the selection of candidates for fecal transplantation for cancer immunotherapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
- Date Crossref
- 03/05/2023
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
SHOWA Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Fukushima Medical University pays non établi dans la noticeUniversité ou école supérieure
-
SHOWA Medical University Hospital pays non établi dans la noticeÉtablissement de santé
-
Keio University pays non établi dans la noticeUniversité ou école supérieure
-
Tokai University Department of Gastroenterological Surgery pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Chest Surgery pays non établi dans la noticeUniversité ou école supérieure
-
School of Pharmacy Department of Hospital Pharmaceutics pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmacy and Graduate School of Pharmaceutical Sciences Division of Biochemistry pays non établi dans la noticeUniversité ou école supérieure
-
Showa University Department of Clinical Immuno Oncology pays non établi dans la noticeUniversité ou école supérieure
SHOWA Medical University, Fukushima Medical University et SHOWA Medical University Hospital, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.